Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine in Relapsed/Refractory Solid Tumors
NCT06494579Phase 2Active, not recruiting
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lamivudine in solid tumor. Started Sep 2024; status: active, not recruiting.
02
Drugs
lamivudine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06494579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494579.